Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 7/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14837095 | 0.85 | PARP1 (0.39) | FTOPOLBALKBH5PARP1 | |
| SCHEMBL917830 | 0.84 | PARP1 (0.37) | FTOPOLBALKBH5PARP1 | |
| SCHEMBL14837487 | 0.80 | ACHE (0.40) | FTOPOLBALKBH5PARP1 | |
| SCHEMBL14837119 | 0.80 | PARP1 (0.38) | FTOPARP1L3MBTL1 | |
| SCHEMBL14837200 | 0.76 | PARP1 (0.43) | PARP1 | |
| SCHEMBL917909 | 0.74 | PARP1 (0.39) | PARP1 | |
| SCHEMBL918327 | 0.73 | CDC7 (0.36) | PARP1 | |
| SCHEMBL14836947 | 0.73 | PARP1 (0.39) | PARP1 | |
| SCHEMBL917641 | 0.73 | PARP1 (0.38) | PARP1 | |
| SCHEMBL14837279 | 0.73 | L3MBTL1 (0.50) | POLBPARP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | claimed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | claimed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | claimed |
| CN-1968929-A | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-05-23 | — | — | CN | claimed |
| EP-1758864-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123687-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-29 | — | — | WO | claimed |
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | FTO 4188/4885POLB 37/4885ALKBH5 2975/4885 |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | FTO 4188/4885POLB 37/4885ALKBH5 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.